Emirates Drug Establishment approves gene replacement therapy for new age group in spinal muscular atrophy patients
UAE becomes world's second country to approve "Itvisma" following US FDA. " Itvisma" is a single-dose, fixed genetic therapy for the treatment of spinal muscular atrophy. Dubai, UAE, December 20, 2025 The Emirates Drug Establishment(EDE) has announced the approval of Itvisma™ (onasemnogene abeparvovec), a gene therapy that uses an adeno-associated viral vector to treat spinal muscular atrophy (SMA) in eligible adults and children aged two years and above. With this decision, the UAE becomes the second country globally to grant approval for this treatment, reinforcing its leadership in accelerating pa
UAE becomes world's second country to approve "Itvisma" following US FDA.
" Itvisma" is a single-dose, fixed genetic therapy for the treatment of spinal muscular atrophy.
Dubai, UAE, December 20, 2025
The Emirates Drug Establishment(EDE) has announced the approval of Itvisma™ (onasemnogene abeparvovec), a gene therapy that uses an adeno-associated viral vector to treat spinal muscular atrophy (SMA) in eligible adults and children aged two years and above.
With this decision, the UAE becomes the second country globally to grant approval for this treatment, reinforcing its leadership in accelerating pa
What's Your Reaction?
Economist Admin
Admin managing news updates, RSS feed curation, and PR content publishing. Focused on timely, accurate, and impactful information delivery.
